Human Herpesvirus-6 Reactivation and Acute Graft-versus-Host Disease

Rashidi, Armin; Said, Bassil; Ebadi, Maryam; Weisdorf, Daniel J.

doi:10.1016/j.bbmt.2018.07.027

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, the results of virological tests must be interpreted with caution 5 . HHV6 is considered as a risk factor of aGVHD, 12 and aGVHD can be associated with viral reactivation. Systematic screening of viral reactivation or primary infection in the context of a skin rash following an allogeneic HCT is then questioned.…”

Section: Discussionmentioning

confidence: 99%

High frequency of cutaneous eruptions within the first year after allogeneic hematopoietic stem cell transplantation

Dambricourt¹,

Bassompierre²,

Calvé³

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

IntroductionThe diagnosis and management of eruptions after hematopoietic cell transplantation (HCT) is a challenge due to their atypical clinical presentation and the biology biased by immunosuppression and graft. The diagnosis is therefore based on multiple grounds. Few studies have focused on the occurrence of a skin rash during the first year of transplantation.ObjectiveTo assess the frequency of rashes in this period, as well as their differential diagnosis and multidisciplinary management.MethodsWe performed a retrospective monocentric descriptive study in the Department of Blood Diseases of Lille University Hospital. All patients who received allogeneic HCT between January 1, 2018, and December 31, 2019, were included.ResultsWe included 196 patients with allogeneic HCT. Of these, 89 (45.4%) presented a skin rash during the first year after transplantation. Among them, 78.7% were diagnosed with acute graft versus host disease (GVHD), 6.7% chemotherapy toxicity, 4.5% chronic GVH, 2.2% of infectious origin and 1.1% drug hypersensitivity. The outcome was mainly favourable (74.2% experienced resolution). A skin biopsy was performed in 9% of cases. Viral polymerase chain reactions (PCRs) were positive in 7.1% of tested patients.DiscussionOur study revealed a high frequency of skin rashes in stem cell transplant patients, thus justifying the multidisciplinary management of these high‐risk patients, which require both dermatological and haematological early expert assessment.

show abstract

Section: Discussionmentioning

confidence: 99%

High frequency of cutaneous eruptions within the first year after allogeneic hematopoietic stem cell transplantation

Dambricourt¹,

Bassompierre²,

Calvé³

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

show abstract

“…1,2 There are many known risk factors such as Human Leukocyte Antigen (HLA) mismatch, high cell dose, and history of total body irradiation 1,3 Infectious triggers, such as human herpesvirus-6 (HHV-6) and CMV reactivation are also well-reported in literature, although the underlying mechanism is not elucidated. 4,5,6,7 The authors share two pediatric cases of acute GVHD exacerbation after SARS-CoV2 infection during the post-transplant period. To date, there is limited literature regarding sequelae of SARS-CoV2 infection in pediatric patients after HSCT.…”

mentioning

confidence: 99%

Acute Exacerbation of Graft-versus-Host Disease following SARS-CoV2 infection after Hematopoietic Stem Cell Transplant in Two Pediatric Patients

Choe

Martinez

Krance

et al. 2022

Preprint

View full text Add to dashboard Cite

“… 1 , 2 There are many known risk factors 1 , 3 including infectious triggers such as human herpesvirus‐6 (HHV‐6) and cytomegalovirus (CMV) reactivation. 4 , 5 , 6 , 7 The authors share two pediatric cases of acute GVHD exacerbation after SARS‐CoV2 infection during the posttransplant period. To date, there is limited literature regarding long‐term sequelae of SARS‐CoV2 in patients after HSCT.…”

mentioning

confidence: 99%

Acute exacerbation of graft‐versus‐host disease following SARS‐CoV2 infection after hematopoietic stem cell transplant in two pediatric patients

Choe

Martinez

Krance

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality in patients receiving hematopoietic stem cell transplant (HSCT), with a reported mortality rate as high as 50% in patients with grade 3-4 GVHD. 1 The complex pathophysiology of GVHD involves donor T-cell activation and cytotoxicity against inflamed host tissue. 1,2 There are many known risk factors 1,3 including infectious triggers such as human herpesvirus-6 (HHV-6) and cytomegalovirus (CMV) reactivation. [4][5][6][7] The authors share two pediatric cases of acute GVHD exacerbation after SARS-CoV2 infection during the posttransplant period. To date, there is limited literature regarding long-term sequelae of SARS-CoV2 in patients after HSCT. [8][9][10][11][12] We aim to bring to light that SARS-CoV2 infection (without COVID-19 disease) may be a potential trigger for acute GVHD exacerbation.Case #1: Patient 1 is a 13-year-old male with history of very high risk recurrent Philadelphia-like B-cell acute lymphoblastic leukemia for which he received a haploidentical bone marrow transplant. Conditioning regimen consisted of fludarabine and total body irradiation.GVHD prophylaxis included post-transplant cyclophosphamide (PT-Cy), mycophenolate mofetil, and tacrolimus. Engraftment occurred 16

show abstract

Human Herpesvirus-6 Reactivation and Acute Graft-versus-Host Disease

Cited by 4 publications

References 8 publications

High frequency of cutaneous eruptions within the first year after allogeneic hematopoietic stem cell transplantation

High frequency of cutaneous eruptions within the first year after allogeneic hematopoietic stem cell transplantation

Acute Exacerbation of Graft-versus-Host Disease following SARS-CoV2 infection after Hematopoietic Stem Cell Transplant in Two Pediatric Patients

Acute exacerbation of graft‐versus‐host disease following SARS‐CoV2 infection after hematopoietic stem cell transplant in two pediatric patients

Contact Info

Product

Resources

About